NCT03890809已完成1 期
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS-986165 in Participants With Normal Hepatic Function and Participants With Mild, Moderate and Severe Hepatic Impairment
Bristol-Myers Squibb4 个研究点 分布在 3 个国家目标入组 32 人开始时间: 2019年2月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 4
- 主要终点
- Maximum observed plasma concentration (Cmax)
研究概览
简要总结
The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body mass index of 18.0 to 38.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
- •Normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) > 80 mL/min/1.73 m2 for participants
排除标准
- •Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant
- •History or clinical evidence of acute or chronic bacterial infection (eg, pneumonia, septicemia) within 3 months prior to screening
- •Have a history of cancer (malignancy) with the following exceptions: (1) participants with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) participants with other malignancies who have been successfully treated ≥10 years prior to the screening visit where, in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the screening visit
- •Other protocol defined inclusion/exclusion criteria could apply
研究组 & 干预措施
Moderate liver impairment
Experimental
Single dose
干预措施: BMS-986165 (Drug)
Normal liver function
Experimental
Single dose
干预措施: BMS-986165 (Drug)
Mild liver impairment
Experimental
Single dose
干预措施: BMS-986165 (Drug)
Severe liver impairment
Experimental
Single dose
干预措施: BMS-986165 (Drug)
结局指标
主要结局
Maximum observed plasma concentration (Cmax)
时间窗: Approximately 9 days
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]
时间窗: Approximately 9 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
时间窗: Approximately 9 days
次要结局
- Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation(Approximately 44 days)
- Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations(Approximately 44 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.Renal ImpairmentHealthy VolunteerNCT03890770Bristol-Myers Squibb44
已完成
1 期
An Investigational Study of Experimental Medication BMS-986165 in Healthy ParticipantsHealthy ParticipantsNCT03660436Bristol-Myers Squibb131
已完成
1 期
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)Infection, Human Immunodeficiency VirusNCT02063360ViiV Healthcare42
已完成
1 期
A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male ParticipantsHealthy ParticipantsNCT05409157Bristol-Myers Squibb7
已完成
1 期
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsHealthy ParticipantsSystemic Lupus ErythematosusNCT03541564Bristol-Myers Squibb84